Lexicon Pharmaceuticals, Inc. (LXRX) Presents at Jefferies London Healthcare Conference 2025 Transcript

Overview - Lexicon has made significant advancements in its pipeline over the past 11 months, indicating a strong performance in 2025 [2] Pipeline Developments - The company has progressed with pilavapadin, a novel AAK1 inhibitor aimed at treating neuropathic pain, having completed the Phase IIb PROGRESS trial [3] - An analysis of the Phase II program's totality of evidence has been conducted, leading to a submission for an end of Phase II meeting request to the FDA along with a briefing book [3] - A meeting with the FDA is scheduled for this year to discuss expectations for the Phase III program, with plans to advance into pivotal trials next year [4]